1. 1 WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine tumours, vol. 8. 5th edn. (International Agency for Research on Cancer, Lyon, France, 2022) https://tumourclassification.iarc.who.int.
2. 2 Chandrasekaran, Kundhavai., Sundaram, Sandhya., Balasubramanian, Subalakshmi. (2023) INSM1 expression in neuroendocrine tumors in a tertiary care hospital. Journal of Cancer Research and Therapeutics doi: 10.4103/jcrt.jcrt_2329_22.
3. 3 Fujino, K., Yasufuku, K., Kudoh, S., Motooka, Y., Sato, Y., Wakimoto, J., et al. (2017) INSM1 is the best marker for the diagnosis of neuroendocrine tumors: Comparison with CGA, SYP and CD56. Int. J. Clin. Exp. Pathol. 10; 5393–5405.
4. 4 Goto, Y., De Silva, M. G., Toscani, A., Prabhakar, B. S., Notkins, A. L. and Lan, M. S. (1992) A novel human insulinoma-associated cDNA, IA-1, encodes a protein with “zinc-finger” DNA-binding motifs. J. Biol. Chem. 267; 15252–15257.
5. 5 Kriegsmann, K., Zgorzelski, C., Kazdal, D., Cremer, M., Muley, T., Winter, H., et al. (2020) Insulinoma-associated protein 1 (INSM1) in thoracic tumors is less sensitive but more specific compared with synaptophysin, chromogranin A, and CD56. Appl. Immunohistochem. Mol. Morphol. 28; 237–242.